Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-09
2010-02-16
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S182000, C514S393000
Reexamination Certificate
active
07662785
ABSTRACT:
This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.
REFERENCES:
patent: 4331647 (1982-05-01), Goldenberg
patent: 4361544 (1982-11-01), Goldenberg
patent: 4444744 (1984-04-01), Goldenberg
patent: 4921690 (1990-05-01), Beaty et al.
patent: 5034223 (1991-07-01), Abrams et al.
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5601819 (1997-02-01), Wong et al.
patent: 5959084 (1999-09-01), Ring et al.
patent: 5985276 (1999-11-01), Lindhofer et al.
patent: 6010902 (2000-01-01), Ledbetter et al.
patent: 6060285 (2000-05-01), Lenz et al.
patent: 6106833 (2000-08-01), Ring et al.
patent: 6210668 (2001-04-01), Lindhofer et al.
patent: 6217871 (2001-04-01), Rose et al.
patent: 2001/0001310 (2001-05-01), Weiner et al.
patent: 2002/0155109 (2002-10-01), Lynch
patent: 2003/0077282 (2003-04-01), Bigler et al.
patent: 2003/0176662 (2003-09-01), Bolognesi et al.
patent: 2004/0242851 (2004-12-01), Zhu
patent: 2005/0079184 (2005-04-01), Hsing-Chang et al.
patent: 2005/0136050 (2005-06-01), Kufer et al.
patent: 2006/0018897 (2006-01-01), Lee et al.
patent: WO 99/53953 (1999-10-01), None
patent: WO/2005/077065 (2005-08-01), None
West et al. Cancer Biotherapy & Radiopharmaceuticals, 2006, vol. 21, pp. 645-654.
Cirino et al. (1999) “Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors.”Infection and Immunity, 67(6):2957-2963.
Cosman et al. (2002) “Identification of Novel Small Molecules That Bind to Two Different Sites on the Surface of Tetanus Toxin C Fragment.”Chem Res Toxicol., 15: 1218-1228.
DeNardo et al. (1998) “Comparison of 1,4,7,10-tetraazacyclododecaine-N,N′,N″,N′″-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.”Clinical Cancer Research, 4(10):2483-2490.
DeNardo et al. (1997) “Yttrium-90/Indium-111-DOTA-peptide-Chimeric L6: Pharmacokinetics, dosimetry and initial results in Patients with incurable breast cancer.”Anticancer Research, 17:1735-1744.
Fan et al. (2000) “AB(5) Toxins: Structures and inhibitor design.”Current Opinion in Structural Biology, 10:680-686.
Henrichsen et al. (1999) “Bioaffinity NMR Spectroscopy: Identification of an E-Selectin Antagonist in a Substance Mixture by Transfer NOE.”Angew Chem Int Edit., 38: 98-102.
Kostelny et al. (2001) “Humanization and characterization of the anti-HLA-DR antibody 1D10.”International Journal of Cancer, 93: 556-65.
Kramer and Karpen (1998) “Spanning binding sites on allosteric proteins with polymer-linked ligand dimers.”Nature, 395:710-713.
Lehnert et al. (2001) “Structure-based design of a bispecific receptor mimic that inhibits T cell responses to a superantigen.”Biochemistry, 40(14): 4222-4228.
Mammen et al. (1998) “Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors.”Angew Chem Int Edit, 37:2755-2794.
Shoichet et al. (2002) “Lead Discovery Using Molecular Docking.”Current Opinion in Chemical Biology, 6: 439-446.
Shuker et al. (1996) “Discovering High-Affinity Ligands for Proteins: SAR by NMR.”Science, 274: 1531-1534.
International Search Report dated Nov. 3, 2005 issued in WO/2005/077065 (PCT/US2005/004134).
Balhorn et al. “Hexa-arginine enhanced uptake and residualization of selective high affinity ligands by Raji lymphoma cells”,Molecular Cancer2009, 8:25, Apr. 22, 2009.
Balhorn et al. “Selective High-Affinity Ligand Antibody Mimics for Cancer Diagnosis and Therapy: Initial Application to Lymphoma/Leukemia”,Clin Cancer Res; 13(18 Suppl) Sep. 15, 2007.
DeNardo et al. “Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma”,International Journal of Oncology31: 729-740 (2007).
DeNardo et al. “Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia.”,International Journal of Oncology34: 511-516 (2009).
DeNardo et al. “Nanomolecular HLA-DR10 Antibody Mimics: A Potent System for Molecular Targeted Therapy and Imaging”,Cancer Biotherapy&Radiopharmaceuticals23(5): 783-796 (2008).
DeNardo et al. “Pharmacokinetic Characterization in Xenografted Mice of a Series of First-Generation Mimics for HLA-DR Antibody, Lym-1, as Carrier Molecules to Image and Treat Lymphoma”,J Nucl Med48: 1338-1347 (2007).
Hok et al. “Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia.”,Bioconjugate Chem. 18, 912-921 (2007).
Balhorn Rodney
DeNardo Gerald
DeNardo Sally
Anderson James D
Lawrence Livermore National Security LLC
Lee John H.
Marschel Ardin
The Regents of California
LandOfFree
Selective high affinity polydentate ligands and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective high affinity polydentate ligands and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective high affinity polydentate ligands and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201734